We are live on ! Find out more
VYGR icon

Voyager Therapeutics
VYGR

116 hedge funds and large institutions have $262M invested in Voyager Therapeutics in 2018 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 32 increasing their positions, 37 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 22

3% less funds holding

Funds holding: 119 → 116 (-3)

3.57% less ownership

Funds ownership: 89.13% → 85.56% (-3.6%)

14% less repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 37

52% less capital invested

Capital invested by funds: $547M → $262M (-$285M)

75% less funds holding in top 10

Funds holding in top 10: 4 → 1 (-3)

Holders
116
Holders Change
-3
Holders Change %
-2.52%
% of All Funds
2.58%
Holding in Top 10
1
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-75%
% of All Funds
0.02%
New
20
Increased
32
Reduced
37
Closed
22
Calls
$248K
Puts
–
Net Calls
+$248K
Net Calls Change
+$126K

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$14.3M
2
Renaissance Technologies
Renaissance Technologies
New York
+$4.58M
3
HCM
Highline Capital Management
New York
+$3.63M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$2.4M
5
SIM
Spark Investment Management
New York
+$1.58M

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$13.3M
2
State Street
State Street
Massachusetts
-$12M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.01M
4
TOPU
Trustees of Princeton University
New Jersey
-$3.85M
5
EAM
Eventide Asset Management
Massachusetts
-$3.43M
Name Holding Trade Value Shares
Change 		Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
$1.37M +$87.7K +6,837 +5%
Two Sigma Investments
27
Two Sigma Investments
New York
$1.32M +$706K +55,055 +64%
T. Rowe Price Associates
28
T. Rowe Price Associates
Maryland
$1.23M -$1.43M -111,232 -46%
SIM
29
Spark Investment Management
New York
$1.16M +$1.58M +123,400 New
Citigroup
30
Citigroup
New York
$1.14M +$719K +56,050 +86%
DM
31
Deerfield Management
New York
$1.11M – – –
Morgan Stanley
32
Morgan Stanley
New York
$1.1M -$3.13M -243,775 -68%
Charles Schwab
33
Charles Schwab
California
$1.07M -$25.5K -1,987 -2%
Two Sigma Advisers
34
Two Sigma Advisers
New York
$932K -$15.4K -1,200 -1%
Invesco
35
Invesco
Georgia
$911K +$1.24M +96,909 New
Bank of New York Mellon
36
Bank of New York Mellon
New York
$831K +$45.5K +3,543 +4%
Allianz Asset Management
37
Allianz Asset Management
Germany
$766K -$39.9K -3,107 -4%
AA
38
ALPS Advisors
Colorado
$707K +$229K +17,844 +31%
HP
39
Harbourvest Partners
Massachusetts
$684K – – –
OAM
40
Oxford Asset Management
United Kingdom
$627K +$855K +66,665 New
Prudential Financial
41
Prudential Financial
New Jersey
$620K -$10.1K -790 -1%
PFGIA
42
Patriot Financial Group Insurance Agency
Massachusetts
$576K +$9.42K +734 +1%
SG Americas Securities
43
SG Americas Securities
New York
$575K +$635K +49,478 +423%
TCIM
44
TIAA CREF Investment Management
New York
$540K -$257K -20,037 -26%
EAM
45
Erste Asset Management
Austria
$529K +$756K +58,900 New
AQR Capital Management
46
AQR Capital Management
Connecticut
$466K +$393K +30,608 +161%
TA
47
Teachers Advisors
New York
$465K – – –
AWM
48
Aevitas Wealth Management
Massachusetts
$454K -$180K -14,023 -23%
Acadian Asset Management
49
Acadian Asset Management
Massachusetts
$433K +$591K +46,031 New
Credit Agricole
50
Credit Agricole
France
$430K +$1.28K +100 +0.2%
1
2
3 4 5

VYGR Hedge Fund Activity: Q4 2018 in Review

116 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q4 2018, worth a combined $262M — down 52% from $547M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of VYGR and 20 opened new positions — a net loss of 2 holders — while 37 trimmed existing stakes and 32 added.

The largest buyer was Armistice Capital, adding an estimated $14.3M. The largest seller was Great Point Partners, cutting an estimated $13.3M.

  • 116 institutional investors held Voyager Therapeutics (VYGR) as of Q4 2018, down from 119 in Q3 2018.
  • Funds reported $262M of Voyager Therapeutics stock for Q4 2018, down 52% quarter-over-quarter.
  • 20 funds opened new Voyager Therapeutics positions in Q4 2018 and 22 closed out, a net change of -2 holders.
  • The largest Voyager Therapeutics buyer in Q4 2018 was Armistice Capital, an estimated $14.3M added.
  • The largest Voyager Therapeutics seller in Q4 2018 was Great Point Partners, an estimated $13.3M sold.

Based on aggregated 13F filings for Q4 2018.